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Summary A novel tumour system has been used to study the effect of natural killer cells on tumour growth
by using agents which modify natural killer cell activity. The tumour cells are hybridoma cells which secrete
antibody specific for red blood cells so that tumour growth can be quantitated by a haemolytic plaque assay.
Spleen-seeking variants have been derived from original hybrids which are sensitive to natural killer cells.
Treatment of mice with polyinosinic-polycytidylic acid substantially enhanced natural killer cell activity and
correlated closely with a reduction in the growth of the hybridoma tumour cells in the spleen and life
extension. Conversely, a single injection of anti-asialo GM1 antibody resulted in a substantial increase in the
number of plaque forming splenic tumour cells and virtual elimination of natural killer cell activity. These
data demonstrate the important role of natural killer cells in constraining the growth of a tumour of B cell
origin and establishes the usefulness of this tumour model in studying the biology of effects on tumour
growth.
Natural killer (NK) cells have the ability to lyse certain
tumour cells in vitro and are recognised as a potentially
important anti-tumour effector mechanism in vivo. Several
types of investigations have been carried out in order to
understand the relationship of the host's non-adaptive
immune system to the development of tumours and their
metastatic spread. Adoptive transfer of purified rat large
granular lymphocytes, cells closely associated with NK
activity, has been shown to decrease the number of
pulmonary metastases of MADBI06 adenocarcinoma cells
(Barlozzari et al., 1985) in the rat and cultured NK cell
clones when transferred back into mice can inhibit tumour
metastasis and suppress the induction of radiation-induced
thymic leukaemia (Warner & Dennert, 1982). Further
evidence for the role of NK cells in controlling the incidence
of spontaneous or experimentally-induced neoplasia has been
obtained by using agents with modulate NK activity in vivo.
For example, agents 'vhich activate or augment NK activity,
such as adjuvants (Hanna & Burton, 1981) or interferon
(IFN) inducers (Hanna & Fidler, 1981) can decrease the
number of metastases in experimental tumours and mice
rendered selectively NK deficient by injection of anti-asialo
GM1 antibody cannot regulate the growth of an NK
susceptible lymphoma (Kawase et al., 1982). An interesting
correlation has been found between susceptibility to NK cells
and tumourigenicity. Several workers have now shown that
depletion of NK activity in mice with anti-asialo GM1
antibody can influence the survival of tumour cells (Habu et
al., 1981) and cause an increase in their metastatic spread
(Gorelik et al., 1982). In addition to these investigations
other studies involving mice congenitally deficient in NK
activity have focussed attention on the role of NK cells in
controlling tumour growth. For example an increase in the
number of B16 melanoma lung metastases in beige mice
correlates with low levels of NK cell activity (Talmage et al.,
1980).
In many of these investigations the quantitation of tumour
growth relies on counting colonies on the surface of an
organ or measuring the tumour diameter. We have recently
described a murine tumour model system where the tumour
cells are hybridomas derived from a myeloma cell fused with
a normal B cell which secretes anti-red blood cell antibody
(Ezaki & Marbrook, 1985). Consequently tumour growth
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can be followed by measuring plaque forming cells in a given
organ or the presence of antibody in the blood, in an
extremely quantitative manner. In this present report we
have used two spleen seeking variants, one of which secretes
anti-bovine red blood cell (BRBC) antibody and the other
anti-horse red blood cell (HRBC) antibody, in order to study
the effect of splenic NK cells on the growth of B cell derived
tumours by employing agents which modify NK cell activity.
Materials and methods
Mice
Male and female, (BALB/c x DBA/2) F1 H-2d (designated
CDF1), CBA/J H-2k, DBA/2 H-2d and (CBA x DBA)F1
mice aged 9-12 weeks were obtained from the mouse colony
in the School of Medicine University of Auckland. They
were age and sex matched for each experiment.
Hybridoma cells
Two hybridoma cell lines, one secreting monoclonal
antibody (IgG) directed against BRBC (Abo-1) and the
other secreting monoclonal antibody (IgM) directed against
HRBC (HeC3) were isolated following the fusion of BALB/c
antibody-forming cells and the myeloma NS-1 (H-2d) as
described previously (Skinner & Marbrook, 1981). The
hybridomas were passaged several times in young BALB/c
mice and two variant sublines were derived designated BSp
and HeSp (Ezaki & Marbrook, 1985). These two
tumourigenic variants grew as spleen colonies in normal
adult CDF1 and BALB/c mice, but would not grow in
DBA/2, CBA/J or (CBAxDBA)F1 mice. Once isolated, a
stock of the spleen-seeking variant cell lines was frozen.
After 4-5 in vivo passages the cell line was discarded and
fresh cells were taken from the frozen stock. In vivo passaged
tumours were used for all in vivo experiments. BSp did not
grow in vitro but HSp could also be maintained in culture.
Eighty to ninety percent of hybridoma cells were plaque-
forming cells.
In vivo augmentation of natural killer cell activity
Polyinosinic-polycytidylic acid (Sigma, St Louis, MO) (poly
I-C) was dissolved in PBS at 1 mgml - and stored at 4°C.
Mice were injected with 0.1 ml poly I-C solution, according
to the method of Djeu et al. (1979), 24h prior to removal of
spleens.
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Cytotoxic assay for NK cells
Fresh spleen cells were incubated with 5 x 103 51Cr-labelled
YAC-1 or HeC3 cells for 4h at a range of killer to target
ratios. After 4h the 51Cr released into the supernatant was
counted in a gamma analyser and percent specific lysis was
calculated as described previously (Ezaki et al., 1983).
Plaque reduction assay for cytotoxicity
The plaque reduction assay was carried out as previously
described (Skinner & Marbrook, 1981; Ezaki et al., 1984).
Briefly, graded numbers of fresh spleen cells were incubated
with 103 HeC3 cells and after 24h the number of HeC3
plaque-forming cells (PFC) was determined on a HRBC
monolayer. Control wells contained HeC3 alone and
cytotoxicity was expressed as percent plaque reduction (PR)
PFC in experiment PR=P100- . xl100. PFC in control
Anti-asialo GM1 treatment
Rabbit anti-asialo GM1 serum was obtained from Wako
Pure Chemical Industries, Osaka, Japan. Lyophilised
antiserum was reconstituted in distilled water and diluted 1
in 20 in PBS. Mice were treated i.v. with 0.2ml of this
concentration of antiserum. In one experiment mice received
0.2ml of a I in 5 dilution. After 4 days fresh spleen cells had
lost their cytotoxic activity against YAC-1 cells as measured
in a 4h "Cr release assay but they showed no decrease in
their ability to be stimulated in vivo by allogeneic cells to
generate cytotoxic T lymphocytes (CTL) capable of killing
the appropriate allogeneic target cell. In addition, in vitro
treatment of hybridoma cells with anti asialo GM1
antiserum and complement did not affect the viability of
these cells as measured by their ability to form PFC.
Assay for hybridoma cell growth in vivo
The growth parameters of the BSp subline have been
reported previously (Ezaki & Marbrook, 1985). The cells
grew exponentially in the spleen with a doubling time of
12h. The HeSp line had similar growth characteristics but
had a doubling time in vivo of - 19h. Consequently, a
standard tumour cell inoculum (6 x 105 viable cells) was
injected i.v. and the rate of tumour growth was assessed by
the number of specific PFC in the spleen after 14 days (BSp)
or 17 days (HeSp) as previously described, (Ezaki &
Marbrook, 1985).
Test for statistical significance
The probability that the difference between two experimental
groups was not due to chance variation was estimated by
using the two sample t-test (Huntsberger & Leaverton, 1970).
P values are shown and those smaller than 0.05 were
considered to be statistically significant, and smaller than
0.01 as highly significant.
Results
Hybridoma cells are NK targets
In order to establish that the hybridoma tumour cells were
killed by cytotoxic cells occurring naturally in fresh splcen
cells, spleen cell suspensions from normal and poly I-C
treated mice were tested for their ability to kill HeC3 cells in
a 4h 51Cr release assay. The ability of these targets to be
killed by spleen cells from a number of mouse strains was
compared with the extent to which the NK sensitive tarigct
YAC-1 was killed. Although HeC3 were not as susceptible
to lysis by fresh spleen cells as YAC-l the strain distribution
of NK activity was similar. Cells from CBA/J mice had high
NK activity, (CBA/DBA) F1 cells had intermediate NK
activity and DBA and CDFI cells had the lowest NK
activity measured with either YAC-1 or HeC3 target cells
(Figure 1).
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Figure 1 Natural killer cell sensitivity of hybridoma cells.
Natural killer cell activity of spleen cells from CBA/J (0)
(CBA x DBA) F1 (0) CDF, (0) and DBA/2 (n) mice which
had been treated once with poly I-C 24h previously (A, B) or
untreated (C, D) was measured on YAC-1 (A, C) or HeC3
hybridoma (C, D) target cells by a 4h 51Cr release assay at a
range of killer to target ratios. Standard deviations of triplicate
assays did not exceed 4% specific lysis.
Poly I-C treatment decreases tumour growth
As poly I-C is a potent inducer of IFN which in turn
increases the NK activity of spleen cells (Gidlund et al.,
1978) the effect of treating mice with poly I-C on tumour
growth was determined. CDF1 mice received their first dose
of poly I-C 24h before tumour inoculation (6 xl05 HeSp)
and then at 48h intervals for 12 days. Seventeen days after
receiving tumour cells, individual mice were assayed for
splenic NK activity by their ability to kill YAC-1 targets and
for tumour growth by individual tumour PFC. There was a
positive correlation between the NK activity in the spleen
and a lack of tumour growth. Spleens from poly I-C treated
mice which were high in NK activity, had less than 300 PFC
tumour cells per spleen and two mice had no detectable
tumour cells at the time of assay. Untreated mice which had
low NK activity had at least 3 x 104 PFC tumour cells per
spleen (Figure 2).
The survival of mice after poly I-C treatment was also
compared with that of untreated animals. The mean survival
time of mice inoculated with HeSp was increased from 21 to
34 days after treatment. Likewise the survival time of mice
inoculated with BSp was increased from 22 days in untreated
mice to 34 days in poly I-C treated animals (Figure 3). An
additional effect with the BSp tumour was that treated mice
became paraplegic 3-4 days prior to death and histological
examination of the femur showed that the tumour had
metastasised to the bone marrow in these mice (data not
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Figure 2 Tumour growth and natural killer cell activity after
poly I-C treatment. CDF1 mice received 6 x 105 HeSp tumour
cells and were either untreated (0) or treated with poly I-C 24h
prior to tumour inoculation and then on alternate days for 12
days (-). Natural killer cell activity measured by the lysis of
51Cr labelled YAC-1 targets and HeSp tumour growth measured
by the number of splenic PFC were quantitated for individual
spleens on day 17. Difference in tumour growth between treated
and control groups is highly significant (P<0.01).
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Influence of anti-asialo GM1 antiserum on tumour cell growth
Mice were treated with anti-asialo GM1 antiserum and their
spleen cells were then tested for the ability to kill HeC3 cells
as measured by a 4h 51Cr release assay and to prevent
growth and kill HeC3 by a 24h plaque reduction assay. The
results depicted in Figure 4A clearly demonstrate that
treatment with the antiserum decreases NK activity
measured on HeC3 target cells. In Figure 4B the assay is the
plaque reduction assay and although the antibody diminishes
the ability of the spleen cells to cause a reduction in tumour
PFC it is not as marked as the reduction measured by 51Cr
release. Interestingly there is little difference in the cytotoxic
activity of poly I-C treated spleen cells compared with
untreated cells, except at high effector cell numbers,
suggesting that other types of cytotoxic activity may be
measured by the plaque reduction technique.
A further group of mice which had been treated with anti-
asialo GM1 antiserum were injected with 6 x IO' HeSp
tumour cells and after 17 days their spleens were assayed for
growth of tumour cells by PFC. A marked difference was
noted in the appearance of spleens which had been treated,
compared with controls (Figure 5). The spleens from treated
animals were considerably larger and had many more
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Figure 4 Cytotoxic activity of spleen cells from anti-asialo GM1
antibody treated mice. CDF1 mice received anti-asialo GM1
antibody i.v. (10/il or 50pl) and were poly I-C treated or
untreated 24h before their spleens were assayed for cytotoxic
activity by 51Cr release using HeC3 targets (A) or inhibition of
HeC3 plaque formation on a HRBC monolayer (B). 0: poly I-C
treated control; 0: untreated control; *: poly I-C treated+anti-
asialo GM1 Ab, (10,ul); l: poly I-C treated+anti-asialo GM1
Ab, (50iil); A: untreated+anti-asialo GM1 Ab. Standard
deviation of triplicate assays by 51Cr release did not exceed 5%
specific lysis. Standard deviation of 5 replicate assays by PR did
not exceed 10% PR.
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Figure 3 Increase in survival after poly I-C treatment. CDF,
mice received 6 x 105 HeSp tumour cells (A) or 6 x 105 BSp
tumour cells (B) and were poly I-C treated (--- -) or untreated (-)
24h prior to tumour inoculation and then on alternate days for
12 days. Means survival times were: (a) poly I-C treated 34.0+2.2
days, untreated 21.7±3.9, P<0.01; (b) poly I-C treated 34.4+4.8,
untreated 22.4+2.1, P<0.01.
Figure 5 Tumour growth in three representative samples from
(A) controls (B) anti-asialo GM. antibodv treated mice.
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tumour 'colonies'. When the tumour PFC were measured
there was an increase in the mean number of tumour cells
with 5.6+1.8 x 105 PFC in the treated compared to 3.2
+2.3 x 104 PFC in control mice (P<0.01). These results
clearly demonstrate the qualitative and quantitative effects of
removing NK cells from tumour bearing mice with anti-
asialo GM1 antiserum.
Tumour growth in young mice
As tumour lines were originally selected in young mice when
NK activity is low (Herberman et al., 1975) the growth of
the hybridoma variants was compared in young (3-4 week
old) and mature (12 week old mice). There were 10 times
more tumour cells in the young mice compared to adult mice
at the time of assay and this correlated with a lower NK
activity measured by the killing of both HeC3 and YAC-1
by Cr release (Table I).
Table I The effect of age on NK activity and tumour growth.
Lytic units of NK activity per
spleen
PFC per
Age of mice spleena HeC3 targets YAC-I targets
3-4 weeks 1.6 x 107 + 1.2 29 131
12 weeks 1.4x 106+1.1 133 556
aMean of 7 mice each group. CDF1 mice were injected with
6 x 105 HeSp cells and spleens assayed for PFC after 17 days. NK
activity in mice poly I-C treated 24h previously. Lytic units defined
as concentration of fresh spleen cells required to give 20% specific
lysis of HeC3 or YAC-1 target. Difference in tumour growth
between two groups is statistically significant (P<0.02).
Discussion
A number of previous investigations in mice and rats have
attempted to demonstrate an in vivo role for natural killer
cells in the control of the growth of transplantable tumours
and in the inhibition of spontaneous or experimentally
induced metastases (Hanna & Burton, 1981; Warner &
Dennert, 1982; Barlozzari et al., 1985). Although blood
borne metastases are likely targets for NK cell activity, it is
generally accepted that the overall 'level' of NK cells may
not reflect the concentration in crucial sites for potential
control of tumour growth (Moore, 1985). With this in mind,
the growth of tumour cells was followed at a site where the
NK cell concentration is readily measured and can be
modulated by extrinsic agents. The hybridoma tumour cell
sublines grow predorninantly in the spleen and can be
measured accurately as haemolytic plaque forming cells.
Even though the spleen-seeking variants proliferate in an
organ which is usually regarded as NK-rich, they may in fact
proliferate within a particular permissive microenvironment
of the spleen.
The sensitivity of hybridoma cells to NK cytotoxicity has
been studied in some detail, particularly in relation to the
rate of killing and the competitive recognition of targets by
NK cells (Ezaki et al., 1983). All hybridomas tested,
including the parent myeloma, NS-1, from which the
hybridoma was derived, are sensitive to NK cells and
selection of hybridomas after successive cycles of treatment
with NK populations have not yielded NK resistant lines
(unpublished results). In the in vitro analysis of HeC3, it is
not lysed as readily as YAC-1 cells (Figure 1) but it is
important to note that the hierarchy of NK activity in the
spleens from different strains of mice is the same whether
measured by YAC-1 or HeC3. When the advantages of using
the plaque reduction assay were used, it should be noted that
80% reduction in PFC could be observed (Figure 4B).
We have adopted a protocol which can quite clearly
increase or decrease NK activity in the target organs of the
hybridoma and have used injections of the double stranded
polynucleotide poly I-C and antibody directed against asialo
GM1 to increase or decrease NK activity. Injection of poly
I-C, a potent inducer of IFN, one day before tumour
inoculation and continued on alternate days for 12 days,
increased the survival time of mice carrying both spleen-
seeking variants and resulted in a marked decrease in
tumour growth after 14-17 days (Figures 2 and 3). The
importance of IFN inducers in boosting NK activity is well
established (Djeu et al., 1979) and high NK activity in poly
I-C treated mice correlated with a reduction of tumour
growth. However, the study of the effect of IFN-inducers
raises the question of whether direct or indirect effects are
being observed. There are direct effects of IFN on tumour
growth (Gresser & Tovey, 1978), and activated macrophages
(Kleineman et al., 1983) or lymphokine-activated killer cells
(Grimm et al., 1982) may also be involved. A single dose of
poly I-C increases NK activity and enhancement only lasts
for a short time. Repetitive treatments were required in this
study, as increase in survival and decrease in tumour growth
is related to the length of time of treatment with poly I-C
(unpublished observations). If this form of treatment is to
provide a means of immunotherapy for cancer patients then
the adverse effects of repetitive injections, such as fever,
reduced haemopoiesis, coagulation and autoimmune disease
must be overcome. Recently a non-toxic mismatched
analogue of poly I-C has been successful in enhancing NK
activity and reducing P77 tumour lung surface colonies in
rats (Nolibe et al., 1985) and may prove to be a useful
immunotherapeutic agent.
Natural killer cells can be depleted in mice and rats by
injecting the animals with anti-asialo GM1 antibody and
although some T lymphocytes are positive for asialo GM,
such treatment has virtually no effect on T cell responses
(Gorelik et al., 1982; & unpublished observations). Our data
clearly demonstrate that anti-asialo GM, antibody treatment
reduces the number of cytotoxic cells in both a normal
spleen and the spleen of poly I-C treated animals (Figure 4).
It is of interest that, at very high effector to target ratios,
there was actually an inhibition of killing (Figure 4B). This
phenomenon has been observed with 51Cr release assays
(unpublished observations) but is particularly marked in the
sensitive PR assay at effector to target ratios of 3000 to I
and long incubation times. These data emphasize the
problems of measuring the action of cytotoxic cells which
are present at very low frequencies. Currently, it cannot be
deduced whether the apparent inhibition of killing is
attributable to non-optimal conditions for cytotoxic cell
activity or whether there are cells which suppress the normal
cytotoxic activity of NK cells.
Tumour growth in mice after treatment with anti-asialo
GM, antiserum was substantially reduced but whether this
effect is due to a defined subset of NK cells remains to be
elucidated. As more antibodies become available which react
with different subsets of NK cells it should be possible to
determine the subset(s) which may be involved in the control
of tumour growth and metastases.
Newborn mice have low levels of NK activity and it is still
low in the spleen at 3-4 weeks coMnpared to adult 12 week
old mice (Table I). Increased tumour growth correlates with
this low activity in young mice although other mechanisms
of immune constraints are also immature at this age. It has
to be borne in mind that measurement of NK cells depends
on the concentration of cytotoxic cells. The growth of
tumour cells in the spleen will reduce the concentration of
NK cells in suspension and could also act as cold target
inhibitors in cytotoxicity assays. The influence of these
factors on assays for NK cell activity has been studied
previously (Ezaki et al., 1983) and do not influence the
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In summary the present study in which the corrlelation
between NK cell levels and the rate of tumour growth at the
same site has been followed provides further evidence that
NK cells may play an important role in the control of
tumour growth and demonstrates the potential use of this
novel tumour system for studying methods of immuno-
therapy which may be useful in the treatment of cancer.
This work was supported by the Medical Research Council of New
Zealand and the Auckland Medical Research Foundation.
References
BARLOZZARI, T., LEONHARDT, J., WILTROUT, R.H., HERBERMAN,
R.B. & REYNOLDS, C.W. (1985). Direct evidence for the role of
LGL in the inhibition of experimental tumor metastases. J.
Immunol., 134, 2738.
DJEU, J.Y., HEINBAUGH, J.A., HOLDEN, H.T. & HERBERMAN, R.B.
(1979). Augmentation of mouse natural killer cell activity by
interferon and interferon inducers. J. Immunol., 122, 175.
EZAKI, T. & MARBROOK, J. (1985). The use of hybridoma cells as a
murine model to study tumour immunity. Int. J. Cancer, 35, 107.
EZAKI, T., SKINNER, M.A. & MARBROOK, J. (1983). Spontaneous
cytotoxic T cells in murine spleen-cell cultures II distinguishing
between spontaneous cytotoxic T cells and NK cells according to
kinetics and target selectivity. Immunology, 50, 351.
EZAKI, T., CHRISTENSEN, N.D., SKINNER, M.A. & MARBROOK, J.
(1984). The adaptation of the plaque reduction assay for
measuring specific cytotoxic cells in limiting dilution cultures. J.
Immunol. Meths., 66, 357.
GIDLUND, M., ORN, A., WIGZELL, M., SENIK A. & GRESSER, I.
(1978). Enhanced NK cell activity in mice injected with
interferon and interferon inducers. Nature, 273, 759.
GRESSER, I. & TOVEY, M.G. (1978). Antitumour effects of
interferon. Biochim. Biophys. Acta, 516, 231.
GRIMM, E.A., MAZUMDER, A., ZHANG, H.Z. & ROSENBERG, S.A.
(1982). Lymphokine activated killer cell phenomenon. Lysis of
natural killer-resistant fresh solid tumor cells by interleukin 2-
activated autologous human peripheral blood lymphocytes. J.
Exp. Med., 155, 1823.
GORELIK, E., WILTROUT, R.H., OKUMURA, K., HABU, S. &
HERBERMAN, R.B..(1982). Role of NK cells in the control of
metastatic spread and growth of tumor cells in mice. Int. J.
Cancer, 30, 107.
HABU, S., FUKUE, H., SHIMAMURA, K. & 4 others. (1981). In vivo
effects of anti-asialo GMV. 1. Reduction of NK activity and
enhancement of transplanted tumour growth in nude mice. J.
Immunol., 127, 34.
HANNA, N. & BURTON, R.C. (1981). Definitive evidence that natural
killer (NK) cells inhibit experimental tumor metastasis in vivo. J.
Immunol., 127, 1754.
HANNA, N. & FIDLER, I.J. (1981). Expression of metastatic potential
of allogeneic and xenogeneic neoplasms in young nude mice.
Cancer Res., 41, 438.
HERBERMAN, R.B., NUNN, M.E. & LAURIN, D.H. (1975). Natural
cytotoxic reactivity of mouse lymphoid cells against syngeneic
and allogeneic tumours. I Distribution of reactivity and
specificity. Int. J. Cancer, 16, 216.
HUNTSBERGER, D.V. & LEAVERTON, P.E. eds. (1970). Statistical
inference in the biochemical sciences. Allyn and Baron Inc.,
Boston.
KAWASE, I., URDAL, D.L., BROOKS, C.G. & HENNEY, C.S. (1982).
Selective depletion of NK cell activity in vivo and its effect on the
growth of NK sensitive and NK resistant tumour cell variants.
Int. J. Cancer, 29, 567.
KLEINEMAN, E.S., SCHROIT, A.J., FOGLER, W.E. & FIDLER, I.J.
(1983). Tumoricidal activity of human monocytes activated in
vitro by free and liposome-encapsulated human lymphokines. J.
Clin. Invest., 72, 1.
MOORE, M. (1985). Natural immunity to tumours - theoretical
predictions and biological observations. Br. J. Cancer, 52, 147,
(Editorial).
NOLIBE, D., AUMAITRE, E. & THANG, M.N. (1985). In vitro
augmentation of rat lung natural killer cell activity and inhibition
of experimental metastases by double-stranded polynucleotides.
Cancer Res., 45, 4774.
SKINNER, M.A. & MARBROOK, J. (1981). The measurement of
cytotoxicity by the reduction of hybridoma plaque-forming cells.
J. Immunol. Meths., 42, 171.
TALMADGE, J.E., MYERS, K.M., PRIEUR, D.J. & STARKEY, J.R.
(1980). Role of NK cells in tumour growth and metastasis in
beige mice. Nature, 284, 622.
WARNER, J.F. & DENNERT, G. (1982). Effects of a cloned line with
NK activity on bone marrow transplants, tumour development
and metastasis in vivo. Nature, 300, 31.